The company just opened a shop in San Diego, and celebrated by out-licensing some of its core technology to New Merck -- in the development of an "undisclosed" vaccine candidate. Under prior owners, it struck a similar deal with Pfizer in 2005. In any event, here is a link to Xconomy|San Diego's story of this morning, and a snippet:
. . . .Pfēnex. . . today says it has granted Merck an exclusive worldwide license to use its technology to produce specific proteins for use in developing an undisclosed vaccine. . . .
Pfēnex says its licensing deal with Merck represents its second commercial license for its proprietary Pfēnex Expression Technology. The biotech did not identify its previous licensee, although Dowpharma, which previously operated Pfēnex as part of Dow Chemical, disclosed plans to work with Pfizer in 2005 to use its technology to help Pfizer develop a protein-based drug that was not identified. Financial details of the agreement were not disclosed at the time. . . .
LATER(12.17.09): FierceVaccines now reports the above deal-value with Merck at $52 million -- paid to Pfēnex.
No comments:
Post a Comment